Literature DB >> 6539984

Studies on crystalluria in calcium oxalate stone formers.

C Ahlstrand, H G Tiselius, L Larsson.   

Abstract

The excretion of calcium oxalate and calcium phosphate crystals was studied in fractionated 24 h urine from 7 men with recurrent calcium oxalate stone disease, both before and during daily administration of 5 mg bendroflumethiazide. Urinary calcium, oxalate, magnesium, citrate, phosphate, pH, and inhibition of calcium oxalate crystal growth rate were analyzed in all samples. Exclusively calcium oxalate crystals were found in 30 per cent of the samples, all with a pH below 6.25, whereas calcium phosphate was the crystal type encountered in urine with a pH above 6.50. Bendroflumethiazide decreased the volume of calcium phosphate but not of calcium oxalate crystals. During the period of observation there was no correlation between calcium oxalate supersaturation and calcium oxalate crystal volume, but a relationship was demonstrated between calcium phosphate supersaturation and calcium phosphate crystal volume.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6539984     DOI: 10.1007/bf00257173

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  14 in total

1.  Changes in the composition of urinary tract stones.

Authors:  A Hodgkinson; R W Marshall
Journal:  Invest Urol       Date:  1975-09

2.  Calcium oxalate crystalluria and inhibitors of crystallization in recurrent renal stone-formers.

Authors:  W G Robertson; M Peacock
Journal:  Clin Sci       Date:  1972-10       Impact factor: 6.124

3.  A method for measuring calcium crystalluria.

Authors:  W G Robertson
Journal:  Clin Chim Acta       Date:  1969-10       Impact factor: 3.786

4.  Particulate activity in urine.

Authors:  D N Adamthwaite
Journal:  Br J Urol       Date:  1983-02

5.  Inhibition of calcium oxalate crystal growth in urine during treatment with allopurinol.

Authors:  H G Tiselius
Journal:  Br J Urol       Date:  1980-06

6.  A biochemical basis for grouping of patients with urolithiasis.

Authors:  H G Tiselius; L E Almgård; L Larsson; B Sörbo
Journal:  Eur Urol       Date:  1978       Impact factor: 20.096

7.  Crystalluria in normal subjects and in stone formers with and without thiazide and cellulose phosphate treatment.

Authors:  P C Hallson; G A Rose
Journal:  Br J Urol       Date:  1976

8.  Variations in urine composition during the day in patients with calcium oxalate stone disease.

Authors:  C Ahlstrand; L Larsson; H G Tiselius
Journal:  J Urol       Date:  1984-01       Impact factor: 7.450

9.  Calcium and oxalate concentrations in human renal tissue: the key to the pathogenesis of stone formation?

Authors:  R Hautmann; A Lehmann; S Komor
Journal:  J Urol       Date:  1980-03       Impact factor: 7.450

10.  An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease.

Authors:  H G Tiselius
Journal:  Clin Chim Acta       Date:  1982-07-15       Impact factor: 3.786

View more
  5 in total

1.  Effects of different doses of alkaline citrate on urine composition and crystallization of calcium oxalate.

Authors:  C Berg; L Larsson; H G Tiselius
Journal:  Urol Res       Date:  1990

2.  Acute oral alkali citrate load in healthy humans--response of blood and urinary citrate, mineral metabolism, and factors related to stone formation.

Authors:  P O Schwille; J H Weippert; W Bausch; G Rümenapf
Journal:  Urol Res       Date:  1985

Review 3.  A hypothesis of calcium stone formation: an interpretation of stone research during the past decades.

Authors:  Hans-Göran Tiselius
Journal:  Urol Res       Date:  2011-01-19

4.  Studies on the role of calcium phosphate in the process of calcium oxalate crystal formation.

Authors:  Hans-Göran Tiselius; Bengt Lindbäck; Anne-Marie Fornander; Mari-Anne Nilsson
Journal:  Urol Res       Date:  2009-05-15

5.  Citrate and recurrent idiopathic calcium urolithiasis. A longitudinal pilot study on the metabolic effects of oral potassium sodium citrate administered as short-, medium- and long-term to male stone patients.

Authors:  U Herrmann; P O Schwille; H Schwarzlaender; I Berger; G Hoffmann
Journal:  Urol Res       Date:  1992
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.